Hidradenitis Suppurativa


Below is a list of our hidradenitis suppurativa studies that are currently enrolling.

A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients with Moderate to Severe Hidradenitis Suppurativa

  • Population: Adult subjects of 18 to 65 years of age with moderate to severe HS
  • Study Condition: Moderate to severe hidradenitis suppurativa diagnosed with recurrent inflammatory lesions for at least 12 months. Subjects need to have at least 3 to 5 inflammatory lesions (abscesses and nodules) in at least two anatomical areas to be included depending on which cohort(s) are open at the time.
  • Study Design: Phase 2, double-blinded, placebo-controlled study to assess the efficacy, safety and tolerability of the investigational drug. Participants will be randomized to receive different doses of investigational drug or its corresponding placebo. 
  • Compensation is provided for participation
  • Study is currently enrolling


Please contact Dr. Carolina Porter for more information regarding ongoing hidradenitis suppurativa studies. 


Email: portecar@musc.edu

Phone: (843) 876-0110